Castle Biosciences (CSTL) Operating Leases (2021 - 2026)

Castle Biosciences has reported Operating Leases for 6 years, with the latest figure at $24.9 million in Q2 2026.

• Quarterly Operating Leases fell 1.9% year-over-year to $24.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $24.9 million (down 1.9% YoY) and the FY2025 annual result came in at $25.2 million, up 75.79% from the prior year.
• Operating Leases fell to $24.9 million in Q2 2026 per CSTL's latest filing, from $25.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $25.4 million in Q2 2025 and troughed at $6.5 million in Q2 2022.
• A 5-year average of $15.8 million and a median of $14.0 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2026: Operating Leases soared 91.77% in 2023, then retreated 1.9% in 2026.
• Over 5 years, Operating Leases stood at $11.5 million in 2022, then advanced by 22.89% to $14.2 million in 2023, then rose by 1.21% to $14.3 million in 2024, then soared by 75.79% to $25.2 million in 2025, then slipped by 1.28% to $24.9 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $24.9 million, $25.1 million, and $25.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.